Pharma Weekly Roundups
🚀 Weekly Pharma News Roundup
19 August 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
🔊 Medicare Price Cuts from IRA Negotiations Slash Big Pharma Blockbusters by Up to 79% Diabetes treatments saw the steepest cuts: Merck's Januvia dropped 79%, and Novo Nordisk's Fiasp dropped 76%.
🔊 Gilead's Livdelzi (seladelpar) Receives Accelerated FDA Approval for Primary Biliary Cholangitis
🔊 Incyte and Syndax’s Niktimvo™ (axatilimab-csfr) Receives FDA Nod for Chronic Graft-Versus-Host Disease Treatment
🔊 ARS Pharma Receives FDA Approval for First Epinephrine Nasal Spray to Treat Type I Allergic Reactions
🔊 Galderma Secures FDA Approval for Nemluvio (nemolizumab) Targeting Adult Prurigo Nodularis
🔊 Ascendis Pharma's YORVIPATH (palopegteriparatide) Receives FDA Approval for Adult Hypoparathyroidism
🔊 AstraZeneca's Imfinzi (durvalumab) Receives FDA Priority Review for Limited-Stage Small Cell Lung Cancer
🔊 Astellas' Gastric Cancer Drug Vyloy (zolbetuximab) Gains Approval from UK Regulator
🔊 Merck Invests $700M in Curon's Bispecific Drug for Immune Disease Potential
🚀 Weekly Pharma News Roundup 🚀
12 August 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
🔊 Adaptimmune Receives FDA Accelerated Approval for TECELRA for Advanced Synovial Sarcoma
🔊 FDA Approves Servier's First-In-Class Groundbreaking Therapy for Two Rare Brain Cancers
🔊 FDA Grants Expanded Approval for GSK’s Jemperli (dostarlimab) Combination for Endometrial Cancer
🔊 FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For IgAN Kidney Disease
🔊 Agios to Receive $1.1B in Milestone Payments After FDA Approval of Vorasidenib
🔊 FDA Approves Citius Pharma's LYMPHIR (denileukin diftitox) Immunotherapy for Cutaneous T-Cell Lymphoma
🔊 FDA Approves Expanded Use of Octapharma's Fibryga for Fibrinogen Deficiency, Setting a New Standard of Care
🔊 FDA Approves Amneal Pharma’s Crexont (formerly IPX203), a Carbidopa/Levodopa ER Capsule, for Parkinson's Disease
🔊 FDA Approves Ocugen's Expanded Access Program for OCU400 Gene Therapy for Retinitis Pigmentosa
🔊 FDA Grants Orphan Drug Status to Cellectis's Alemtuzumab in R/R B-cell acute lymphoblastic leukemia
🚀 Weekly Pharma News Roundup 🚀
5 August 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
🔊 Pfizer Receives Conditional Authorization from EC for DURVEQTIX Gene Therapy in Hemophilia B
🔊 Luye Pharma's Extended-Release Injectable Suspension ERZOFRI for Schizophrenia and Schizoaffective Disorder Receives FDA Approval
🔊 Boehringer Ingelheim to Acquire Nerio Therapeutics for Up to $1.3B in a Strategic Move Towards Immuno-Oncology
🔊 Japan’s Otsuka Pharma to Buy Jnana Therapeutics for Up to $1.1B
🔊 Prelude Forms New Partnership with Merck to Evaluate PRT3789 for Cancers Associated with the SMARCA2 and SMARCA4 Genes
🚀 Weekly Pharma News Roundup 🚀
29 July 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
🔊Phathom Pharma Receives FDA Approval for VOQUEZNA for Heartburn Relief in Adults with Non-Erosive GERD
🔊Sun Pharma Secures US FDA Approval for LEQSELVI for Alopecia Areata in Adults
🔊Novartis and Dren Bio Sign Potential $3B Partnership for Bispecific Antibodies Targeting Cancer
🔊Australia's Telix Secures $398M in Debt Funding to Boost Kidney and Brain Cancer Radiotherapies
🔊Grünenthal Completes $250M Acquisition of Valinor Pharma and its OIC Therapy, Movanti
🔊SIGA Secures $113M Procurement Option with U.S. Health and Human Services (HHS) for Oral Antiviral Tpoxx
🔊Ipsen Gains Ex-US Rights to Day One's Pediatric Cancer Drug Tovorafenib with $111M Upfront Investment
🔊AstraZeneca Signs $45M+ Licensing Deal with Pinetree for Preclinical EGFR Degrader
🔊LTR Pharma Raises $10.5M to Advance SPONTAN for Erectile Dysfunction
🔊Sionna Therapeutics Enhances Pipeline with Clinical-Stage Cystic Fibrosis Compounds via AbbVie License Agreement
🔊Cytoki Pharma’s CK-0045 Reduces Cardiometabolic Risk Factors in Positive Phase I Study
🚀 Weekly Pharma News Roundup 🚀
22 July 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
🔊 AstraZeneca Completes $1.05B Acquisition of Amolyt Pharma Focused on Rare Endocrine Diseases
🔊 CordenPharma Invests €900M to Enhance Peptide Platform Amid Rising GLP-1 Drug Demand
🔊 Roche's New GLP-1 Weight Loss Pill Causes Drop in Novo Nordisk and Eli Lilly Shares
🔊 Pfizer Moves Forward with Clinical Trials for New Weight-Loss Pill Danuglipron
🔊 Silo Pharma Secures Exclusive Global License for Alzheimer's Drug SPC-14
🔊 AGC Pharma Chemicals and AbilityPharma Collaborate on Pancreatic Cancer Treatment
🔊 Genentech’s Cystic Fibrosis Drug Improves Outcomes in Severe COVID-19 Pneumonia
🔊 FDA Accepts Eton Pharma's NDA for ET-400 with PDUFA Target Date Set for Feb 28, 2025
🔊 Neuren Pharmaceuticals Receives Rare Pediatric Disease Designation for NNZ-2591 for Phelan-McDermid syndrome
🔊 Vertex Invests $15M in Orum Licensing to Enhance Gene Editing Capabilities
🚀 Weekly Pharma News Roundup 🚀
15 July 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
🔊 New Labour Government Supports Pharmaceutical Reforms in the UK
🔊 Eli Lilly's $3.2B Acquisition of Morphic Aims to Boost its Drug Portfolio for IBD and Other Chronic Conditions
🔊 Merz Therapeutics Plans US Workforce Expansion After Acquiring Acorda’s Inbrija and Ampyra for $185M
🔊 Takeda Inks $100M Option Deal with Ascentage for CML Treatment
🔊 Ligand Pharma Completes $100M Acquisition of Apeiron Biologics
🔊 Pfizer Advances with Once-Daily Weight Loss Pill Danuglipron Despite Previous Challenges
🚀 Weekly Pharma News Roundup 🚀
8 July 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
🔊 Eli Lilly’s Kisunla Cleared by FDA Panel for Alzheimer’s
🔊 Europe greenlights Dupixent by Sanofi and Regeneron, marking the first biologic for COPD
🔊 FDA Declines Rocket Pharma's Gene Therapy for Severe Pediatric Immune Disorder, Requests More Info
🔊 Viatris Completes $3.37B Sale of OTC Business to Cooper Consumer Health
🔊 Eli Lilly Forms $140M Partnership with Radionetics Oncology, Expands Radiopharmaceuticals Presence
🔊 Radiopharma Specialist Pentixapharm Acquires Glycotope's Preclinical Cancer Antibody Division
🔊 Amylyx Acquires Rights to Eiger Biopharmaceutical’s Avexitide for $35.1M
🚀 Weekly Pharma News Roundup 🚀
1 July 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
🆕 After 20 years, the FDA approves Verona's Ohtuvayre, a novel mechanism inhaler for COPD
🤝 Lilly Partners with OpenAI to Discover Novel Treatments for Drug-Resistant Bacteria
💰 EvolutionaryScale Biotech Raises $142M for AI-Driven Drug Discovery
💵 Zealand Pharma Sells $1B in Shares to Finance Obesity Drug Projects
📈 Shanghai Henlius Biotech Sees Stock Surge in Hong Kong After $690M Buyout Offer from Fosun
🚀 Alnylam Pharma Shares Surge 30% After Rare Heart Disease Drug Outperforms Pfizer’s Drug
💔 Merck KGaA Drops Xevinapant After Phase III Failure in Head and Neck Cancer
🚀 Weekly Pharma News Roundup 🚀
24 June 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
🌟 Sarepta’s Gene Therapy Elevidys Gains US Approval for Expanded Use in Treating DMD
🏅 Merck's Keytruda Secures 40th US Indication for Broad First-Line Endometrial Cancer, Leaping Ahead of GSK
❌ Radiopharmaceutical Specialist Telix Cancels $232M NASDAQ IPO Last Minute
💸 Marea Therapeutics Secures $190M to Advance Next-Generation Cardiometabolic Therapies
🤝 AbbVie Invests $150M in Preclinical IBD Drug from FutureGen for TL1A Competition
🛡️ Gilead's Twice-Yearly Lenacapavir Exhibited 100% Efficacy and Superiority to Daily Truvada in HIV Prevention
🚀 Weekly Pharma News Roundup 🚀
17 June 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
📈 ONO Completed the Acquisition of Deciphera Pharmaceuticals for $2.4B
🔬 Ipsen's Iqirvo Receives FDA Accelerated Approval for Rare Liver Disease
✅ FDA Expands Approval of GSK's RSV Vaccine Arexvy for At-Risk Adults 50-59
💉 Moderna's Combo COVID-19/Flu Vaccine Elicits a Stronger Immune Response in Adults Over 50 Than Separate Shots
🚀 Weight Loss and Alzheimer’s Drugs Propel Eli Lilly Shares to a 48% Increase in 2024
🚀 Weekly Pharma News Roundup 🚀
11 June 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
🧬 Moderna Gains Second FDA Approval for mRNA-Based RSV Vaccine
💊 Novartis Leukemia Drug Scemblix Beats Older Drugs in Phase III Readout
💼 Sanofi Completes $1.7B Acquisition of Inhibrx
📉 Sanofi Proceeds with €20B Consumer Healthcare Division Spin-Off
🔬 Rare-Disease Drug Maker Cycle Pharma Bids $466M for US-based Vanda
🚀 Weekly Pharma News Roundup 🚀
4 June 2024
Stay in the lead with last week's top pharmaceutical industry highlights! 📈💊
💉 J&J Acquires NM26 Bispecific Antibody for Atopic Dermatitis from Numab for $1.25B
💊 Eli Lilly Boosts Lebanon, Indiana Investment to $9B to Expand Tirzepatide Production
🇯🇵 Japanese Asahi Kasei to Acquire Swedish Calliditas Therapeutics for $1.1B
🇪🇺 European Commission Approves €1B for First Health Sector Project of Common Interest
🌍 Advocates Urge Broad Availability of Gilead's "game-changing" Twice-yearly HIV Drug
🚀 Weekly Pharma News Roundup 🚀
28 May 2024
Stay ahead of the curve with the top pharmaceutical industry highlights from last week! 📈💊
🤖 Sanofi, Formation Bio, and OpenAI Announce AI Collaboration
💼 Takeda's $1.2 Billion Deal with China-based Degron Therapeutics
📈 Targeted Radiopharmaceuticals Market Growth: A $25 Billion Market
🌍 Serum Institute Ships First Malaria Vaccine to Africa
📉 Biopharma Layoff Tracker
DeepMind's AlphaFold 3: A game-changer for drug discovery
8 May 2024
AlphaFold, developed by Google's DeepMind subsidiary, is an AI program that predicts protein structures from their amino acid sequences.
This is a crucial step in drug discovery, as understanding protein structure is essential for designing effective drugs.
AlphaFold 3's accuracy has been lauded by scientists, with Google’s AI chief estimating its commercial potential to be over $100 billion.
M&A surge in the radiopharmaceuticals sector...
2 May 2024
Novartis' breakthrough with Pluvicto has triggered a wave of mergers and acquisitions in the radiopharmaceuticals sector among major pharmaceutical companies. These targeted treatments deliver radiation directly to cancer cells while preserving healthy tissue. However, challenges like scarcity of radioactive materials and quick administration needs persist.
According to RBC Capital Markets, the radiopharmaceuticals market is expected to grow to $25 billion, with Novartis leading the way.
Despite the positive forecast, competition from other targeted cancer therapies is a factor that Big Pharma companies must take into account.